On September 30, GRAIL, Inc. rose 5.27% in regular trading, trading at $144.035 per share, with turnover of $24.4235 million. The stock extended its recent upward momentum following the FDA Molecular and Clinical Genetics Devices Advisory Committee's favorable vote on the company's Galleri multi-cancer early detection test premarket approval application.

The committee's 10 voting members unanimously approved Galleri's safety profile at 10-0, voted 6-4 in favor of its efficacy, and 7-2 in favor of the benefit-risk assessment for adults aged 50 and older. Data from the PATHFINDER 2 study showed that adding Galleri to standard screenings increased cancer detection 6.5-fold, with 71% of newly identified cancers detected at stages I through III. UBS maintained its buy rating, noting the positive panel vote has nearly \"de-risked\" the approval pathway, while market expectations for formal FDA clearance continue to build.

GRAIL, Inc. is a healthcare company focused on early cancer detection, leveraging next-generation sequencing and large-scale clinical studies. Its Galleri blood test has demonstrated the ability to detect over 50 cancer types from a single blood draw with high signal-of-origin accuracy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)